Kronos Bio, Inc. (KRON)
Automate Your Wheel Strategy on KRON
With Tiblio's Option Bot, you can configure your own wheel strategy including KRON - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol KRON
- Rev/Share 0.1512
- Book/Share 1.3125
- PB 0.5116
- Debt/Equity 0.3018
- CurrentRatio 12.9297
- ROIC -0.6769
- MktCap 40940818.0
- FreeCF/Share -0.8942
- PFCF -0.7529
- PE -0.6332
- Debt/Assets 0.2228
- DivYield 0
- ROE -0.6422
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 4
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Shareholder Alert: The Ademi Firm Investigates Whether Kronos Bio, Inc. is Obtaining a Fair Price for Its Public Shareholders
Published: May 01, 2025 by: Business Wire
Sentiment: Neutral
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Kronos (Nasdaq: KRON) for possible breaches of fiduciary duty and other violations of law in its transaction with Concentra. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, shareholders of Kronos will receive only $0.57 per share, plus one contingent value right, which represent.
Read More
Kronos Bio Enters into Agreement to Be Acquired by Concentra Biosciences for $0.57 in Cash per Share Plus a Contingent Value Right
Published: May 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. ("Kronos Bio") (Nasdaq: KRON), a biotechnology company that has been developing small molecule therapeutics to address cancers and other diseases driven by deregulated transcription, today announced that it has entered into a definitive merger agreement (the “Merger Agreement”) with Concentra Biosciences, LLC ( “Concentra”), whereby Concentra will acquire Kronos Bio for $0.57 in cash per share of Kronos Bio common stock (“Kronos Bio Common Stock”), plus one non-tradeable contingent value right ("CVR"), which represents the right to receive: (i) 50% of the net proceeds in the case of a …
Read More
About Kronos Bio, Inc. (KRON)
- IPO Date 2020-10-09
- Website https://kronosbio.com
- Industry Biotechnology
- CEO Dr. Deborah A. Knobelman Ph.D.
- Employees 8